Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Heart Failure; Rosuvastatin; Positron Emission Tomography (PET)

Treatments: Procedure: Positron emission tomography; Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00228514

4522IL/0098 Dutch SubStudy

D3562C00098

Details and patient eligibility

About

At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve)

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.

Exclusion criteria

• See above

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind